Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.

Mean change from baseline in scores on the global health status/QoL subscale showed a trend for deterioration with successive fulvestrant plus sapanisertib daily treatment cycles, while scores remained close to baseline in the single-agent fulvestrant and fulvestrant plus sapanisertib weekly arms (Supplementary Fig.

also in 53,322 other papers

PFS was numerically longer with both sapanisertib plus fulvestrant combination regimens than with fulvestrant alone; however, the treatment differences did not reach statistical significance, so the primary study endpoint was not met.

also in 111,027 other papers